Breadcrumb

Breadcrumbs

Oncology History Main Article

Daiichi Sankyo Oncology Timeline

An overview of Daiichi Sankyo's progress in the fight against cancer:

Oncology History

  • April 2016

    Antoine Yver, MD, MSc, appointed to Global Head, Oncology Research and Development, responsible for leading global research and development across the oncology therapeutic area

  • 2016
    March 2016

    Daiichi Sankyo announced 2025 Vision to become a "Global Pharma Innovator with a Competitive Advantage in Oncology"

  • March 2016

    Phase 3 METIV-HCC of tivantinib to continue until final analysis per recommendation from independent data monitoring committee

  • 2015
    December 2015

    Patient accrual completed for phase 3 METIV-HCC study of tivantinib

  • November 2015

    Combimetinib plus Zelboraf received FDA approval. Began co-promotion in the US with Genentech

  • 2015
    October 2015

    Pexidartinib granted Breakthrough Therapy Designation by the FDA for the treatment of tenosynovial giant cell tumor (TGCT)

  • August 2015

    Generic name for PLX3397, pexidartinib, recommended by the International Nonproprietary Names (INN) for Pharmaceutical Substances

  • 2015
    July 2015

    PLX3397 phase 1 extension data published in The New England Journal of Medicine

  • November 2014

    Acquired Ambit Biosciences to expand oncology pipeline

  • 2014
    February 2014

    PLX3397 granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA)

  • October 2013

    Tivantinib granted Orphan Drug Designation by FDA

  • 2012
    April 2012

    Launched Ranmark® (denosumbab) in Japan for treatment of bone complications stemming from multiple myeloma and bone metastases from solid tumors.

  • August 2011

    Received FDA approval of Zelboraf® (vemurafenib). Co-promotion with Genentech began.

  • 2011
    April 2011

    Acquired Plexxikon Inc. for oncology pipeline and drug development

  • March 2009

    Quizartinib granted Orphan Drug Designation by the FDA (received by Ambit Biosciences prior to becoming part of Daiichi Sankyo)

  • 2008
    November 2008

    Entered into licensing agreement with ArQule Inc. to co-promote MET inhibitor tivantinib

  • May 2008

    Acquired U3 Pharma, a company with a pipeline of targeted antibody therapeutics for cancer

  • 1995
    1995

    Received approval of irinotecan in Japan, the first chemotherapy to demonstrate survival benefits in colorectal cancer

  • 1985

    Launched the first natural-type interferon beta preparation for brain tumor and skin cancer in Japan

  • 1977
    1977

    Launched Krestin® (Polysaccharide-K) in Japan to treat digestive, lung and breast cancer

daiichi-sankyo-oncology-pipeline-in-the-united-states-QuickLink

More Stories

Phase 3 Oncology Compounds

Daiichi Sankyo currently has three compounds in phase 3 clinical development with unique mechanisms of action...

read more ...